Silicone Components for Infusion And IV Therapy Devices: Compliance Requirements And Supplier Selection

Intravenous infusion sets are among the highest-volume medical devices manufactured globally — with an estimated 15–20 billion units produced annually. Every one of those sets contains silicone components: pump segments, injection ports, drip chamber seals, and in many designs, the primary fluid path tubing itself. The silicone in an IV infusion set is in direct contact with drugs, blood products, and parenteral nutrition solutions that flow directly into the patient's bloodstream — the most demanding drug-contact application in all of medicine.

The consequences of silicone component failure in an IV infusion set are immediate and potentially life-threatening. Particulate contamination from a poorly manufactured silicone component can cause pulmonary embolism. Extractables leaching from an inadequately cured compound can interact with drug formulations, reducing efficacy or creating toxic degradation products. A pump segment that loses dimensional precision causes infusion rate errors — a critical safety issue in high-alert medication administration (insulin, heparin, chemotherapy).

For IV device manufacturers, the silicone component specification and supplier selection decisions made during product development determine patient safety outcomes for the life of the product. This guide gives you the complete technical and regulatory framework for making those decisions correctly.

Part 1: Silicone Components in an IV Infusion Set — Anatomy of the Fluid Path

Before specifying silicone components, it is essential to understand where silicone appears in a standard IV infusion set and what functional role each component plays.

The Standard Gravity IV Infusion Set — Component Breakdown

A standard gravity IV infusion set consists of the following components, moving from the drug container to the patient:

1. Spike / Vented SpikePierces the IV bag or bottle. Typically rigid PVC or ABS — silicone not standard here, though silicone venting membranes are used in some designs.

2. Drip ChamberAllows visual monitoring of flow rate (drops per minute). Typically rigid PVC or PP housing with a silicone or rubber filter membrane at the base. The filter membrane prevents air passage while allowing fluid flow — a critical function that depends on the membrane's surface tension properties.

3. Primary TubingThe main fluid conduit from drip chamber to patient. Typically medical-grade PVC in gravity sets. In pump-driven sets and specialty applications, silicone tubing is used for the primary fluid path — particularly where PVC plasticizer (DEHP) is a regulatory concern or where drug compatibility with PVC is an issue.

4. Pump Segment (Peristaltic Pump Sets)The section of tubing that passes through the peristaltic pump head. This is the most technically demanding silicone component in an IV set — it must withstand millions of compression cycles while maintaining dimensional precision for accurate flow rate delivery. Silicone is the only material suitable for peristaltic pump segments — PVC fatigues rapidly under repeated compression and loses dimensional stability.

5. Injection / Y-SitesPorts for secondary medication administration. Typically silicone rubber septum in a rigid housing — the septum must reseal completely after needle or needleless connector access to prevent leakage and contamination.

6. In-Line FilterRemoves particulates and air from the fluid path. Silicone is used for the filter housing seal and sometimes the filter membrane support.

7. Flow Regulator / ClampControls flow rate. Typically PVC or PE — silicone not standard.

8. Luer ConnectorConnects to the IV catheter hub. Typically rigid PC or ABS — silicone not standard.

Where Silicone Is Irreplaceable

Of the components above, three represent applications where silicone is either the industry standard or the only technically viable material:

Part 2: The Pump Segment — The Most Critical Silicone Component in IV Therapy

Why Pump Segment Specification Is a Patient Safety Issue

Peristaltic infusion pumps deliver medications by repeatedly compressing and releasing a segment of tubing — the pump segment — to move fluid forward. The volumetric flow rate delivered to the patient is directly determined by:

Q=π×(ID2)2×Locclusion×RPM×ηQ=π×(2ID)2×Locclusion×RPM×η

Where QQ is flow rate, IDID is inner diameter, LocclusionLocclusion is the occluded length per roller, RPMRPM is pump speed, and ηη is volumetric efficiency (affected by compression set and tube recovery).

The critical insight: Flow rate scales with the square of inner diameter. A 5% variation in ID produces a 10% variation in flow rate. For high-alert medications — insulin (units/hour), heparin (units/hour), chemotherapy agents (mg/m²/hour) — a 10% flow rate error is clinically significant and potentially dangerous.

This is why pump segment dimensional precision is not a quality preference — it is a patient safety requirement.

Pump Segment Specification Parameters

Pump Segment Fatigue Life — What "Millions of Cycles" Means

A peristaltic infusion pump operating at a typical clinical flow rate of 100 ml/hour subjects the pump segment to approximately:

• 3,000–6,000 compression cycles per hour

• 72,000–144,000 cycles per day

• 500,000–1,000,000+ cycles over a 7-day pump set life

At these cycle counts, compression set accumulation is the primary failure mode. As compression set increases, the tube's effective ID decreases — reducing flow rate below the programmed value. Modern infusion pumps have occlusion detection algorithms that compensate partially for tube wear, but dimensional drift beyond the pump's compensation range causes undetected flow rate errors.

Qualification requirement: Pump segment fatigue life must be validated by cyclic compression testing — typically 1,000,000 cycles at the pump's operating occlusion pressure — with flow rate accuracy measured at defined intervals (0, 100k, 250k, 500k, 750k, 1,000k cycles). Acceptance criterion: flow rate accuracy within ±5% of nominal throughout the test.

For the complete technical guide to peristaltic pump tubing selection — including compression set testing protocol, fatigue life validation, and pump head compatibility — see: Peristaltic Pump Tubing Selection: Material Properties and Performance Factors

Part 3: Drug Compatibility — The Most Underspecified Requirement

Drug compatibility is the most frequently underspecified requirement in IV silicone component procurement — and the one with the most serious consequences when it fails.

What Drug Compatibility Means for Silicone

Drug compatibility for silicone IV components has two dimensions:

Dimension 1: Drug stability in contact with siliconeSome drugs adsorb onto silicone surfaces or absorb into the silicone matrix, reducing the drug concentration delivered to the patient. This is particularly significant for:

• Lipophilic drugs: Nitroglycerin, diazepam, amiodarone, cyclosporine — significant absorption into silicone

• Protein-based biologics: Some monoclonal antibodies and proteins adsorb onto silicone surfaces

• Low-concentration high-potency drugs: Where even small losses significantly affect delivered dose

Dimension 2: Silicone extractables in the drug solutionSilicone components release low levels of extractables into contact fluids — primarily low-molecular-weight siloxanes, platinum catalyst residues (in platinum-cured compounds), and any unreacted crosslinker. For most drugs, these extractables are clinically insignificant. For some sensitive formulations, they can cause:

• Drug degradation or precipitation

• Particulate formation

• Altered drug pharmacokinetics

Drug Compatibility Testing Framework

For IV device manufacturers, drug compatibility testing should follow a risk-based approach:

Tier 1: Standard drug compatibility (most IV drugs)

• Verify silicone compound meets FDA 21 CFR 177.2600 (chemical composition limits)

• Verify USP Class VI and ISO 10993-5 cytotoxicity compliance

• Conduct extractables screening (total organic carbon, UV absorbance) in representative extraction media (water, saline, 5% dextrose)

• This level is sufficient for most standard IV medications

Tier 2: Enhanced compatibility testing (high-risk drugs)For drugs with known compatibility concerns (lipophilic drugs, biologics, narrow therapeutic index medications):

• Conduct drug-specific adsorption/absorption studies

• Measure drug concentration at inlet and outlet of silicone tubing after defined contact time

• Acceptance criterion: drug concentration loss ≤ 10% under worst-case contact conditions

Tier 3: Full extractables and leachables (E&L) study (pharmaceutical manufacturing)For silicone tubing used in pharmaceutical manufacturing fluid paths (not just IV administration):

• Full E&L study per ICH Q3C/Q3D guidelines

• Identification and quantification of all extractables above the analytical evaluation threshold (AET)

• Toxicological risk assessment for identified extractables

• This level is required for drug manufacturing equipment, not typically for IV administration sets

High-Risk Drug Categories — Silicone Compatibility Reference

Part 4: Particulate Cleanliness — The Non-Negotiable Requirement

Particulate contamination in IV fluid paths is a direct patient safety risk. Particles entering the bloodstream can cause:

• Pulmonary microembolism (particles >5μm)

• Phlebitis and vascular inflammation

• Granuloma formation (chronic particulate exposure)

• Device malfunction (pump occlusion, filter clogging)

Regulatory Particulate Limits for IV Components

Sources of Particulate Contamination in Silicone IV Components

Understanding contamination sources allows targeted process controls:

Cleanroom Requirements for IV Silicone Component Manufacturing

For silicone components used in IV fluid paths, ISO Class 7 cleanroom (maximum 352,000 particles/m³ at ≥0.5μm) is the minimum acceptable manufacturing environment. ISO Class 8 is acceptable for non-fluid-path components.

Critical cleanroom controls for IV silicone components:

• Positive pressure differential: Cleanroom maintained at positive pressure relative to adjacent areas to prevent particle ingress

• HEPA filtration: 99.97% efficiency at 0.3μm for supply air

• Continuous particle monitoring: Real-time particle counter with alarm limits

• Personnel gowning: Full cleanroom suit, gloves, face mask, shoe covers — no street clothing in cleanroom

• Material entry protocol: All materials entering cleanroom through airlock or pass-through with wipe-down procedure

• Regular environmental monitoring: Particle counts, microbial monitoring (viable and non-viable), temperature and humidity

At Chensheng Medical, our IV-grade silicone tubing and components are manufactured in our ISO Class 7 cleanroom with continuous particle monitoring and full environmental monitoring records available for customer review.

Part 5: Regulatory Standards for IV Infusion Sets — What You Must Comply With

ISO 8536 Series — The Primary Standard Family

The ISO 8536 series defines requirements for infusion equipment for medical use. The most relevant parts for silicone component manufacturers and IV device developers:

Key ISO 8536 Requirements Affecting Silicone Components

Biological evaluation (ISO 8536-1, Clause 5.1):All materials in contact with infusion fluids must be evaluated per ISO 10993-1. For silicone components in IV sets, this requires at minimum: cytotoxicity (ISO 10993-5), sensitization (ISO 10993-10), and systemic toxicity (ISO 10993-11) testing on the finished, sterilized component.

Extractables (ISO 8536-1, Clause 5.2):Materials must not release substances in quantities that could affect the safety or efficacy of the infused medication. This is evaluated through extractables testing in representative extraction media.

Particulate matter (ISO 8536-1, Clause 5.3):Infusion sets must meet particulate cleanliness requirements. The standard specifies test methods for particulate counting and defines acceptance limits.

Flow rate accuracy (ISO 8536-8, Clause 7):For pump-driven infusion sets, flow rate accuracy must be within ±5% of nominal under defined test conditions. This requirement flows directly to pump segment dimensional precision requirements.

Pressure resistance (ISO 8536-8, Clause 8):Pump segments must withstand the maximum occlusion pressure generated by the pump without rupture or permanent deformation. Minimum burst pressure: typically 3× maximum operating pressure.

FDA Regulatory Classification

In the United States, IV infusion sets are regulated as Class II medical devices under:

• 21 CFR 880.5860 — Infusion set

• 21 CFR 880.5900 — Infusion pump

• 510(k) premarket notification required for new infusion set designs

Silicone components used in IV sets must comply with:

• FDA 21 CFR 177.2600 — Rubber articles intended for repeated use (chemical composition requirements)

• FDA 21 CFR 177.2420 — Perfluorocarbon resins (if PTFE components present)

• ISO 10993-1 biological evaluation (FDA-recognized standard per 2016 guidance)

EU MDR Classification

Under EU MDR 2017/745, IV infusion sets are classified as:

• Class IIa (Rule 8 — active therapeutic devices administering substances)

• CE marking via Notified Body required

• Common Specifications for infusion pumps (EU 2022/83) apply to pump-driven sets

For a complete guide to navigating FDA, CE, and NMPA regulatory requirements for medical silicone components, see: FDA vs CE vs NMPA: Navigating Medical Device Regulations for Silicone Components

Part 6: Injection Port Septa — Silicone's Critical Sealing Role

Clinical Function and Requirements

Injection port septa (Y-site septa, additive port septa) are small silicone discs or plugs that seal injection ports in IV sets. They must:

1. Reseal completely after needle or needleless connector access — preventing fluid leakage and microbial contamination

2. Withstand repeated access — typically 50–100 needle insertions without losing sealing integrity

3. Not core — the needle must not cut out a silicone plug that enters the fluid path as a particulate

4. Be compatible with all drugs administered through the port

5. Maintain sterility of the fluid path after access

Silicone Specification for Injection Port Septa

Needleless Connector Compatibility

Modern IV sets increasingly use needleless connectors (positive pressure, negative pressure, or neutral displacement) rather than needle access ports. Silicone septa for needleless connector systems have different requirements:

• Higher reseal force (the connector applies greater opening force than a needle)

• Specific geometry to mate with the connector's activation mechanism

• Compatibility with connector disinfection protocols (IPA wipe, chlorhexidine)

• Validated for the specific connector brand used in the IV set design

Part 7: DEHP-Free Silicone as a PVC Alternative — The Regulatory Trend

The DEHP Problem in IV Tubing

Di(2-ethylhexyl) phthalate (DEHP) is the plasticizer used in standard medical-grade PVC tubing. DEHP leaches from PVC into IV fluids — particularly lipophilic solutions (lipid emulsions, cyclosporine, paclitaxel) — and has been classified as a reproductive toxin (Category 1B) under EU CLP regulation.

Regulatory status of DEHP in medical devices:

• EU MDR: DEHP-containing devices must carry a special label warning; Notified Bodies require justification for continued use

• EU REACH: DEHP is on the SVHC (Substances of Very High Concern) candidate list

• FDA: Has issued guidance recommending DEHP-free alternatives for vulnerable patient populations (neonates, pregnant women, male infants)

• Multiple EU member states: Have implemented restrictions on DEHP in medical devices for pediatric and neonatal applications

Silicone as the DEHP-Free Alternative

Platinum-cured silicone contains no plasticizers — it is inherently DEHP-free. For IV device manufacturers facing DEHP regulatory pressure, silicone tubing offers:

• Zero DEHP leaching — no plasticizer in the compound

• Broader drug compatibility — no plasticizer-drug interactions

• Regulatory compliance — meets EU MDR DEHP labeling requirements without special justification

• Premium positioning — DEHP-free labeling is a marketing advantage in pediatric and neonatal markets

Practical considerations for switching from PVC to silicone:

• Silicone tubing has different mechanical properties than PVC — flow characteristics, kink behavior, and connector fit must be re-validated

• Silicone is more expensive than PVC — cost impact must be assessed for the specific product

• Pump segment performance in silicone is superior to PVC — this is a genuine performance upgrade, not just a regulatory compliance change

• Biocompatibility testing must be repeated for the new silicone material

Part 8: Supplier Qualification — 8 Questions Every IV Device Manufacturer Must Ask

The consequences of silicone component failure in IV therapy are severe enough that supplier qualification must be more rigorous than for lower-risk applications. These eight questions reveal the critical differences between qualified and unqualified suppliers.

1. "What is your cleanroom classification for IV-grade silicone component manufacturing, and can you provide your most recent environmental monitoring report?"ISO Class 7 minimum for IV fluid-path components. Request actual particle count data — not just the classification claim. Environmental monitoring records should show consistent results well within the ISO class limit, not results that barely pass.

2. "Can you provide particulate cleanliness test data for your IV tubing — specifically, particle counts per ISO 8536 or USP <788> methodology?"A qualified IV component supplier conducts routine particulate testing and has data available. A supplier who has never tested particulate cleanliness is not qualified for IV applications.

3. "What is your pump segment dimensional Cpk for ID and OD?"Process capability index (Cpk) measures how well the manufacturing process holds the specified tolerance. For pump segments with ±0.05mm tolerance, Cpk ≥ 1.33 is the minimum acceptable. Cpk < 1.0 means the process is not capable of consistently meeting the tolerance.

4. "Can you provide compression set data for your pump segment compound — specifically ASTM D395 Method B, 22 hours at 70°C?"Compression set ≤ 8% is the target for IV pump segments. A supplier who cannot provide this data has not characterized their compound for pump applications.

5. "Have you conducted drug compatibility testing for your silicone compound? Can you provide extractables data in saline, dextrose 5%, and water?"Basic extractables screening in representative IV media is the minimum. A supplier who has no extractables data for their IV-grade compound cannot support your drug compatibility assessment.

6. "Is your biocompatibility testing conducted on the finished, sterilized component — or only on the raw compound?"ISO 10993-1 requires testing on the finished device in its sterilized state. Compound-only testing is insufficient for IV component qualification. Many suppliers provide only compound-level data — this is a documentation gap that will appear in your regulatory submission review.

7. "What is your process for detecting and preventing particulate contamination during production — specifically, how do you handle a cleanroom excursion?"A qualified supplier has a documented response procedure for cleanroom excursions: production hold, investigation, disposition of potentially affected product, root cause analysis, and CAPA. A supplier without this procedure has not thought through their contamination control system.

8. "Can you provide fatigue life data for your pump segment — specifically, flow rate accuracy after 1,000,000 compression cycles?"This is the ultimate qualification test for pump segments. A supplier who cannot provide this data has not validated their product for pump applications. Without this data, you cannot validate your pump's flow rate accuracy over the intended product life.

For a complete framework for evaluating and qualifying medical silicone suppliers — including remote audit protocols and certificate verification — see: How to Choose a Reliable Medical Silicone Manufacturer in China

For guidance on building supply chain resilience for critical IV component supply, see: Medical Silicone Supply Chain Risk Management: How to Build a Resilient Sourcing Strategy

Part 9: Silicone Tubing Specification for IV Applications — Quick Reference

Standard IV Fluid Transfer Tubing

Peristaltic Pump Segment

Injection Port Septum

Chensheng Medical IV-Grade Silicone Components

Jinan Chensheng Medical Technology Co., Ltd. manufactures IV-grade silicone tubing and components for global infusion set manufacturers, pump manufacturers, and IV therapy device developers.

Our IV-grade product range:

Manufacturing standard for all IV-grade products:

• Platinum-cured silicone compound — no peroxide-cured material in IV product lines

• ISO Class 7 cleanroom manufacturing

• Continuous laser micrometer dimensional monitoring

• ISO 13485 quality management system

• Routine particulate cleanliness testing per ISO 8536

• Full biocompatibility documentation: USP Class VI · ISO 10993-5, -10, -11 · FDA 21 CFR 177.2600

• Lot-specific Certificate of Analysis with every shipment

→ Request IV-Grade Silicone Samples and Specifications→ Discuss Your Pump Segment Requirements→ Contact Our IV Applications Engineering Team

Frequently Asked Questions (FAQ)

Q1: What is the difference between IV-grade and standard medical-grade silicone tubing?

A: IV-grade silicone tubing meets higher standards than general medical-grade tubing in three areas: (1) Particulate cleanliness — IV-grade tubing is manufactured in ISO Class 7 cleanroom conditions with routine particulate testing per ISO 8536 or USP <788>; standard medical-grade may be manufactured in ISO Class 8 with less rigorous particulate controls; (2) Extractables — IV-grade tubing has documented extractables data in representative IV media (saline, dextrose, water); standard medical-grade may have only cytotoxicity and USP Class VI data without fluid-specific extractables characterization; (3) Dimensional precision — IV pump segments require ±0.05mm tolerance with Cpk ≥ 1.33; standard medical tubing is typically held to ±0.10mm. For any silicone tubing in direct contact with IV fluids administered to patients, IV-grade specification is required.

Q2: Which infusion pump brands is your pump segment tubing compatible with?

A: Our pump segments are manufactured to the dimensional specifications provided by the pump manufacturer — we do not maintain a stock of pump-specific segments. To order pump segments for a specific pump, provide us with the pump manufacturer's tubing specification (ID, OD, wall thickness, Shore A hardness, and any special requirements). We have supplied pump segments for use with Baxter, B. Braun, Fresenius Kabi, ICU Medical, and other major infusion pump platforms. For pump segment qualification, we recommend requesting samples and conducting flow rate accuracy testing on your specific pump model before production approval.

Q3: How do I determine if my drug is compatible with silicone tubing?

A: Start with the drug compatibility reference table in Part 3 of this article. For standard IV medications (saline, dextrose, most antibiotics, most opioids), platinum-cured silicone is compatible without drug-specific testing. For lipophilic drugs (nitroglycerin, amiodarone, diazepam), protein-based biologics, or narrow therapeutic index medications, conduct drug-specific adsorption testing: measure drug concentration at the inlet and outlet of your silicone tubing after defined contact time under worst-case conditions (lowest flow rate, longest contact time, highest drug concentration). If drug loss exceeds 10%, consult with your formulation team and consider alternative tubing materials or surface treatments. We can provide silicone tubing samples for your drug compatibility testing and supply our extractables data to support your assessment.

Q4: What Cpk value should I require for pump segment dimensional qualification?

A: For pump segments with ±0.05mm tolerance, the minimum acceptable Cpk is 1.33 — this corresponds to a process that produces fewer than 64 defects per million opportunities (DPMO) at the tolerance limit. For high-volume pump sets where dimensional drift could affect patient safety, Cpk ≥ 1.67 (≤0.6 DPMO) is a more appropriate target. Request Cpk data from your supplier based on a minimum of 30 consecutive production lots, not just a single qualification run. Cpk should be monitored on an ongoing basis and reported in the lot-specific CoA for pump segment production.

Q5: We are developing a DEHP-free infusion set to replace our current PVC design. What do we need to re-validate when switching to silicone tubing?

A: Switching from PVC to silicone tubing for an IV infusion set requires re-validation of: (1) Biocompatibility — new ISO 10993 testing on the silicone tubing in its final sterilized state; (2) Drug compatibility — silicone has different extractables and adsorption characteristics than PVC; drug compatibility testing must be repeated for your formulary; (3) Flow characteristics — silicone tubing has different compliance (wall expansion under pressure) than PVC, affecting flow rate in gravity sets; (4) Connector fit — silicone OD tolerance and stiffness affect connector retention force; verify pull-out force meets ISO 8536 requirements; (5) Pump segment performance — if the set includes a pump segment, validate flow rate accuracy and fatigue life with the silicone segment; (6) Sterilization compatibility — verify EtO or gamma compatibility and re-validate sterilization cycle if packaging changes; (7) Regulatory submission — a 510(k) supplement (US) or Technical Documentation update (EU MDR) is required for a material change to an approved device.

Q6: What is the shelf life of EtO-sterilized silicone IV components, and how is it validated?

A: The standard shelf life for EtO-sterilized silicone IV components is 2–3 years, validated by accelerated aging per ASTM F1980 combined with real-time aging confirmation. Accelerated aging uses elevated temperature storage (typically 55°C or 60°C) to simulate real-time aging — the acceleration factor is calculated using the Arrhenius equation with a Q10 factor of 2 (doubling of aging rate per 10°C temperature increase). For a claimed 2-year shelf life, accelerated aging at 55°C requires approximately 26 weeks of storage before sterile barrier integrity testing. We provide accelerated aging validation data for all our sterile IV-grade products. Extended shelf life (3–5 years) is available for OEM products with specific validation requirements.

Q7: Can silicone pump segments be used in both volumetric and syringe infusion pumps?

A: Silicone pump segments are designed for peristaltic (volumetric) infusion pumps — they are not used in syringe pumps. Syringe pumps use a rigid syringe barrel and plunger mechanism that does not involve tubing compression. For peristaltic pump applications, the pump segment specification must match the specific pump model's requirements — different pump manufacturers use different ID, OD, and wall thickness specifications, and using an incorrectly specified pump segment will cause flow rate errors. Always obtain the pump manufacturer's tubing specification before ordering pump segments, and validate flow rate accuracy on the specific pump model before production approval.

Related Articles:

• Peristaltic Pump Tubing Selection: Material Properties and Performance Factors

• Platinum-Cured vs. Peroxide-Cured Silicone: Which Is Better for Your Application?

• USP Class VI, ISO 10993, and FDA 21 CFR 177.2600: Which Certification Do You Actually Need?

• Sterilization Methods for Medical Silicone Products: Autoclave, EtO, Gamma, and E-Beam Compared

• Silicone Shore A Hardness Explained: How to Select the Right Durometer for Your Medical Application

• How to Choose Medical Grade Silicone Tubing: A Complete Specification and Sourcing Guide

• How to Choose a Reliable Medical Silicone Manufacturer in China

• Medical Silicone Supply Chain Risk Management: How to Build a Resilient Sourcing Strategy